Ribociclib extends median survival by over 12 months in advanced breast cancer

Final analysis of MONALEESA-2 confirms significant OS benefit despite high crossover in the placebo arm

Design MONALEESA-2 Phase 3 Trial Population Postmenopausal women with HR+, HER2- advanced breast cancer N 668 Duration Median follow-up 6.6 years Comparator Placebo + Letrozole Year 2022

Key Performance Indicators

PRIMARY

Hazard Ratio (Death)

0.76

95% CI: 0.63–0.93

24% reduction in risk of death

PRIMARY

Median OS Benefit

+12.5 mo

63.9 vs 51.4 months

Clinically meaningful extension

6-Year Survival Rate

44.2%

vs 32.0% (Placebo)

Long-term durability

01

Ribociclib delays all major progression and survival milestones

The treatment arm showed superior median duration across Overall Survival, Time to First Chemo, and Chemo-free Survival.

02

Survival benefit widens significantly over time

Kaplan-Meier estimates show the absolute difference in survival rates increasing from 5.7% at year 4 to 12.2% at year 6.

03

Survival advantage is consistent across key prognostic subgroups

Hazard ratios favor Ribociclib (<1.0) across age groups and metastatic sites, though confidence intervals widen for smaller subgroups.

04

OS benefit persists despite higher CDK4/6 crossover in Placebo arm

34.4% of placebo patients received a subsequent CDK4/6 inhibitor compared to 21.7% in the Ribociclib arm, potentially diluting the observed OS benefit.

05

Neutropenia is the primary Grade 3/4 adverse event

While neutropenia rates are high in the treatment arm, other severe toxicities like QT prolongation and hepatobiliary effects remain relatively low.

Editorial Conclusion

“Ribociclib plus letrozole demonstrates a statistically significant and clinically meaningful overall survival benefit of over one year compared to placebo.”

Median OS reached 63.9 months, the longest reported in this setting to date.

Benefit is consistent across subgroups and durable at 6 years.

Results are robust even after adjusting for the 34% of placebo patients who crossed over to CDK4/6 inhibitors.

Clinical Implication

These findings support Ribociclib plus Letrozole as a preferred first-line standard of care for postmenopausal patients with HR+/HER2- advanced breast cancer.

Reference Data & Sources

Complete Data Table

viz_id	chart_type	label	group	value	low	high	unit	category	x	y
viz1	dumbbell	Median Overall Survival	Ribociclib	63.9			months	Primary Outcome
viz1	dumbbell	Median Overall Survival	Placebo	51.4			months	Primary Outcome
viz1	dumbbell	Time to 1st Chemo	Ribociclib	50.6			months	Secondary Outcome
viz1	dumbbell	Time to 1st Chemo	Placebo	38.9			months	Secondary Outcome
viz1	dumbbell	Chemo-free Survival	Ribociclib	39.9			months	Secondary Outcome
viz1	dumbbell	Chemo-free Survival	Placebo	30.1			months	Secondary Outcome
viz2	line_chart	4 Years	Ribociclib				%		48	60.9
viz2	line_chart	4 Years	Placebo				%		48	55.2
viz2	line_chart	5 Years	Ribociclib				%		60	52.3
viz2	line_chart	5 Years	Placebo				%		60	43.9
viz2	line_chart	6 Years	Ribociclib				%		72	44.2
viz2	line_chart	6 Years	Placebo				%		72	32.0
viz3	forest	All Patients	Total	0.76	0.63	0.93
viz3	forest	Age <65 Yr	Demographic	0.73	0.56	0.94
viz3	forest	Age ≥65 Yr	Demographic	0.82	0.6	1.12
viz3	forest	Visceral Mets (Liver/Lung)	Disease Status	0.81	0.62	1.05
viz3	forest	Bone-only Lesions	Disease Status	0.78	0.5	1.21
viz3	forest	De Novo Metastatic	History	0.91	0.72	1.15
viz4	stacked_bar	Ribociclib Arm	Received Subsequent CDK4/6	21.7			%
viz4	stacked_bar	Ribociclib Arm	No Subsequent CDK4/6	78.3			%
viz4	stacked_bar	Placebo Arm	Received Subsequent CDK4/6	34.4			%
viz4	stacked_bar	Placebo Arm	No Subsequent CDK4/6	65.6			%
viz5	lollipop	Neutropenia	Ribociclib	63.8			%	Grade 3/4 AE
viz5	lollipop	Neutropenia	Placebo	1.2			%	Grade 3/4 AE
viz5	lollipop	Hepatobiliary toxicity	Ribociclib	14.4			%	Grade 3/4 AE
viz5	lollipop	Hepatobiliary toxicity	Placebo	4.8			%	Grade 3/4 AE
viz5	lollipop	Prolonged QT interval	Ribociclib	4.5			%	Grade 3/4 AE
viz5	lollipop	Prolonged QT interval	Placebo	2.1			%	Grade 3/4 AE

Abbreviations

Abbrev	Meaning
OS	Overall Survival
HR	Hazard Ratio
CI	Confidence Interval
AE	Adverse Event
CDK4/6	Cyclin-dependent kinases 4 and 6

Source

N Engl J Med 2022;386:942-50

DOI: 10.1056/NEJMoa2114663

Limitations

Black patients were underrepresented (2.5%).
High rate of subsequent CDK4/6 use in placebo arm required sensitivity analysis.